Kiora Pharmaceuticals’ (KPRX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at $1.28 EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.

Kiora Pharmaceuticals Stock Performance

Shares of Kiora Pharmaceuticals stock traded down $0.13 during mid-day trading on Tuesday, hitting $3.27. The stock had a trading volume of 17,138 shares, compared to its average volume of 73,577. The firm has a 50-day moving average of $3.52 and a two-hundred day moving average of $4.28. Kiora Pharmaceuticals has a 12-month low of $3.00 and a 12-month high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.09. On average, analysts expect that Kiora Pharmaceuticals will post 0.89 EPS for the current year.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for approximately 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest position. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.